unorthodoxy.substack.com/p/the-power-of-the-clinical-trial-big?just_subscribed=t...
1 correction found
Moderna, a company with no prior commercial products, earned $28 billion from its vaccine in the same period—an astronomical windfall that catapulted the company to global prominence.
Moderna’s own reported vaccine sales for 2021 and 2022 were much higher than $28 billion. Official filings show about $17.7 billion in 2021 and $18.4 billion in 2022, totaling roughly $36.1 billion.
Full reasoning
The article understates Moderna’s vaccine revenue for 2021–2022.
Official Moderna reporting shows:
- 2021 product sales: $17.675 billion from sales of its COVID-19 vaccine.
- 2022 product sales: $18.435 billion from sales of its COVID-19 vaccines.
Together, those figures total $36.110 billion across 2021 and 2022.
That means the article’s claim that Moderna "earned $28 billion from its vaccine in the same period" is inaccurate by more than $8 billion.
2 sources
- Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
Full Year 2022 ... Product sales for 2022 were $18.4 billion ... Product sales | $18,435 | $17,675.
- Moderna 2021 Annual Report on Form 10-K
For the year ended December 31, 2021, we delivered approximately 332 million doses of our COVID-19 vaccine to the U.S. Government and approximately 475 million doses to other governments, and we recognized $17.7 billion in product sales.